Association Between Neuropsychiatric Symptoms and Blood‐Based Autoantibody Biomarkers

Neuropsychiatric symptoms are frequently observed along the Alzheimer disease (AD) continuum. Recent research has shown that blood‐based biomarkers are able to identify early AD‐related pathological changes associated with (1) preclinical AD (before the onset of clinical/functional symptoms), (2) mild cognitive impairment (MCI; with clinical symptoms and relatively spared functional decline), and (3) AD (obvious clinical and functional symptoms). Evidence for the potential diagnostic utility of serum autoantibodies has been extensively studied. The purpose of this study is to explore whether blood levels of specific autoantibodies used in the diagnostic biomarkers panels are linked with specific behavioral changes observed along the AD continuum.